Do you want to read an article? Please log in or register.
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary Endpoints From the EMBARK Trial
Genitourinary Cancer
Related content
Genitourinary Cancer
Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints
J Urol
Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EP, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ
doi: 10.1097/JU.0000000000004879
ESMO 2025
Genitourinary Cancer
EMBARK: Enzalutamide plus leuprolide significantly improves OS in high-risk biochemically recurrent prostate cancer
Genitourinary Cancer
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age
Eur J Cancer
Shore ND, De Giorgi U, Kalac M, Tang Y, Croitoru R, Rosales M, Huynh MJ, de Jong IJ, Evans CP, Carcano FM, Freedland SJ
doi: 10.1016/j.ejca.2025.116110
SPECIAL REPORT
Genitourinary Cancer
EMBARK: Impact of Enzalutamide Plus ADT on Clinical Practice in Biochemically Recurrent Prostate Cancer
COMMENTED
Genitourinary Cancer
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Freedland SJ, Mulhall JP, Gleave M, Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N
doi: 10.1016/j.eururo.2025.02.006
Genitourinary Cancer
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
N Engl J Med
Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Kalac M, Sridharan S, Rosales M, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Wang F, Freedland SJ
doi: 10.1056/NEJMoa2510310
Genitourinary Cancer
Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase 3 trials of docetaxel and zoledronic acid using healthcare systems data
Ann Oncol
Jones C, Dutey-Magni P, Murphy LR, Murray ML, Brown JE, McCloskey E, Brown M, Amos CL, Gilbert DC, Jones RJ, Cross W, Matheson D, Millman R, Parmar MKB, Attard G, Sydes MR, Brown LC, James ND, Clarke NW, Sachdeva A, STAMPEDE Trial Investigators
doi: 10.1016/j.annonc.2025.07.005
Genitourinary Cancer
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis
Eur Urol
Mazzone E, Thomson A, Chen DC, Cannoletta D, Quarta L, Pellegrino A, Gandaglia G, Moon D, Eapen R, Lawrentschuk N, Montorsi F, Siva S, Hofman MS, Chiti A, Briganti A, Perera ML, Murphy DG
doi: 10.1016/j.eururo.2025.05.006
Genitourinary Cancer
Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials
J Clin Oncol
Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko JP, DeVries S, Sartor O, Sandler HM, Mohamad O, Huang HC, Griffin J, Yamashita R, Esteva A, Tran PT, Spratt DE, Carson JH, Peters C, Gore E, Lee SP, Monson JM, Augspurger ME, El-Gayed A, Rodgers JP, McKay R, Morgan T, Feng FY, Nguyen PL
doi: 10.1200/JCO.24.00365